Drugs / MK-6916
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07862621 | Nov 2026 → Feb 2027 expected | — | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06818968 | Feb → Aug 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07862595 | Nov 2026 → Jun 2027 expected | — | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-6916 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07862621 ↗ |
| Route | Oral | “Participants will receive MK-6916 and diltiazem orally.” NCT06818968 ↗ |